[1] |
World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
|
[2] |
Workneh MH, Bjune GA, Yimer SA. Prevalence and asso-ciated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS One, 2017, 12(4): e175925. doi:10.1371/journal.pone.0175925.
|
[3] |
Bates M, Marais BJ, Zumla A. Tuberculosis Comorbidity with Communicable and Noncommunicable Diseases. Cold Spring Harb Perspect Med, 2015, 5(11):a017889. doi:10.1101/cshperspect.a017889.
|
[4] |
Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019, 7(4): e448-e460. doi:10.1016/S2214-109X(18)30487-X.
|
[5] |
Seegert AB, Rudolf F, Wejse C, et al. Tuberculosis and hypertension-a systematic review of the literature. Int J Infect Dis, 2017, 56: 54-61. doi:10.1016/j.ijid.2016.12.016.
|
[6] |
Armstrong LR, Kammerer JS, Haddad MB. Diabetes mellitus among adults with tuberculosis in the USA, 2010—2017 BMJ Open Diabetes Res Care, 2020, 8(1):e001275. doi:10.1136/bmjdrc-2020-001275.
|
[7] |
Reis-Santos B, Gomes T, Locatelli R, et al. Treatment outcomes in tuberculosis patients with diabetes: a polytomous analysis using Brazilian surveillance system. PLoS One, 2014, 9(7): e100082. doi:10.1371/journal.pone.0100082.
|
[8] |
Yorke E, Atiase Y, Akpalu J, et al. The Bidirectional Relationship between Tuberculosis and Diabetes. Tuberc Res Treat, 2017, 2017: 1702578. doi:10.1155/2017/1702578.
|
[9] |
Huaman MA, Henson D, Ticona E, et al. Tuberculosis and Cardiovascular Disease: Linking the Epidemics. Trop Dis Travel Med Vaccines, 2015, 1:10. doi:10.1186/s40794-015-0014-5.
|
[10] |
Rodriguez-Iturbe B, Pons H, Johnson RJ. Role of the Immune System in Hypertension. Physiol Rev, 2017, 97(3): 1127-1164. doi:10.1152/physrev.00031.2016.
|
[11] |
Chidambaram V, Gupte A, Wang JY, et al. The Impact of Hypertension and Use of Calcium Channel Blockers on Tuberculosis Treatment Outcomes. Clin Infect Dis, 2021, 73(9): e3409-e3418. doi:10.1093/cid/ciaa1446.
|
[12] |
中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 结核与肺部疾病杂志, 2024, 5(4): 376-378. doi:10.19983/j.issn.2096-8493.2024022.
|
[13] |
中华人民共和国国家卫生和计划生育委员会. WS 196—2017结核病分类. 结核与肺部疾病杂志, 2024, 5(4): 379-380. doi:10.19983/j.issn.2096-8493.2024055.
|
[14] |
陈明亭, 刘剑君, 赵雁林, 等. 中国结核病防治工作技术指南(2021年版). 北京: 人民卫生出版社, 2021.
|
[15] |
Du Q, Wang L, Long Q, et al. Systematic review and meta-analysis: Prevalence of diabetes among patients with tuberculosis in China. Trop Med Int Health, 2021, 26(12): 1553-1559. doi:10.1111/tmi.13686.
|
[16] |
Wang L, Peng W, Zhao Z, et al. Prevalence and Treatment of Diabetes in China, 2013—2018. JAMA, 2021, 326(24): 2498-2506. doi:10.1001/jama.2021.22208.
|
[17] |
Lin Y, Li L, Mi F, et al. Screening patients with diabetes mellitus for tuberculosis in China. Trop Med Int Health, 2012, 17(10): 1302-1308. doi:10.1111/j.1365-3156.2012.03069.x.
|
[18] |
Harries AD, Kumar AM, Satyanarayana S, et al. Addressing diabetes mellitus as part of the strategy for ending TB. Trans R Soc Trop Med Hyg, 2016, 110(3): 173-179. doi:10.1093/trstmh/trv111.
|
[19] |
Chung WS, Lin CL, Hung CT, et al. Tuberculosis increases the subsequent risk of acute coronary syndrome: a nationwide population-based cohort study. Int J Tuberc Lung Dis, 2014, 18(1): 79-83. doi:10.5588/ijtld.13.0288.
|
[20] |
安源, 白云龙, 赵庆龙, 等. 2018—2022年吉林省肺结核合并糖尿病患者治疗转归情况及影响因素分析. 中国防痨杂志, 2025, 47(4): 432-438. doi:10.19982/j.issn.1000-6621.20240529.
|
[21] |
朱娅梅. 抗结核治疗对患者血压的短期影响及相关因素的研究. 昆明: 昆明医科大学, 2023.
|
[22] |
Lin Y, Harries AD, Kumar A, et al. Tackling diabetes mellitus and tuberculosis: a new Union guide on the management of diabetes-tuberculosis. Int J Tuberc Lung Dis, 2019, 23(7): 771-772. doi:10.5588/ijtld.19.0119.
|
[23] |
梁达, 赵晓银, 商越, 等. 青海省结核病患者治疗结局影响因素分析及贝叶斯网络模型研究. 疾病监测, 2022, 37(2): 210-213. doi:10.3784/jbjc.202103230151.
|
[24] |
谭卫国, 管红云, 吴清芳, 等. 流动人口结核病防控创新策略与实施效果. 新发传染病电子杂志, 2020, 5(3): 145-149. doi:10.19871/j.cnki.xfcrbzz.2020.03.001.
|
[25] |
杨蕊, 李玲, 陈金瓯, 等. 2017—2021年云南省肺结核与糖尿病共病患者抗结核治疗效果及影响因素分析. 中国防痨杂志, 2024, 46(5): 519-524. doi:10.19982/j.issn.1000-6621.20240006.
|
[26] |
Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med, 2011, 9: 81. doi:10.1186/1741-7015-9-81.
|
[27] |
Huangfu P, Ugarte-Gil C, Golub J, et al. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. Int J Tuberc Lung Dis, 2019, 23(7): 783-796. doi:10.5588/ijtld.18.0433.
|
[28] |
刘海妮, 华中秋, 张少茹, 等. 结核病患者心理困扰现状及其影响因素分析. 现代预防医学, 2020, 47(4): 665-668. doi:10.20043/j.cnki.mpm.2020.04.021.
|
[29] |
Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol, 2018, 34(5): 575-584. doi:10.1016/j.cjca.2017.12.005.
|
[30] |
Ayelign B, Negash M, Genetu M, et al. Immunological Impacts of Diabetes on the Susceptibility of Mycobacterium tuberculosis. J Immunol Res, 2019, 2019: 6196532. doi:10.1155/2019/6196532.
|
[31] |
蒋泽顺, 杨正贵, 李江平, 等. 宁夏结核病治疗转归影响因素分析及预测模型的建立. 现代预防医学, 2021, 48(16): 2905-2910. doi:10.20043/j.cnki.mpm.2021.16.006.
|
[32] |
汪娟, 许缃, 姜静, 等. 2013—2017年上海市徐汇区糖尿病并发肺结核患者特征登记转归分析. 结核病与肺部健康杂志, 2019, 8(1): 29-32. doi:10.3969/j.issn.2095-3755.2019.01.008.
|
[33] |
国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 等. 结核病与糖尿病共病的治疗管理专家共识. 中国防痨杂志, 2021, 43(1): 12-22. doi:10.3969/j.issn.1000-6621.01.004.
|
[34] |
Meng F, Lan L, Wu G, et al. Impact of diabetes itself and glycemic control status on tuberculosis. Front Endocrinol (Lausanne), 2023, 14: 1250001. doi:10.3389/fendo.2023.1250001.
|
[35] |
Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months? Chest, 2015, 147(2): 520-528. doi:10.1378/chest.14-0918.
|
[36] |
魏建华, 高小娜, 郭蕾. 利福平引起血压升高的原因分析. 宁夏医学杂志, 2016, 38(10): 966-967. doi:10.13621/j.1001-5949.2016.10.0966.
|